Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Resmed (RSMDF) Payables (2016 - 2025)

Historic Payables for Resmed (RSMDF) over the last 16 years, with Q4 2025 value amounting to $510.3 million.

  • Resmed's Payables rose 12166.37% to $510.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $510.3 million, marking a year-over-year increase of 12166.37%. This contributed to the annual value of $288.1 million for FY2025, which is 1632.65% up from last year.
  • As of Q4 2025, Resmed's Payables stood at $510.3 million, which was up 12166.37% from $526.7 million recorded in Q3 2025.
  • In the past 5 years, Resmed's Payables ranged from a high of $526.7 million in Q3 2025 and a low of $129.2 million during Q1 2021
  • Moreover, its 5-year median value for Payables was $189.4 million (2022), whereas its average is $229.1 million.
  • In the last 5 years, Resmed's Payables tumbled by 502.66% in 2023 and then skyrocketed by 12166.37% in 2025.
  • Over the past 5 years, Resmed's Payables (Quarter) stood at $175.4 million in 2021, then rose by 17.41% to $205.9 million in 2022, then rose by 3.1% to $212.3 million in 2023, then rose by 8.44% to $230.2 million in 2024, then soared by 121.66% to $510.3 million in 2025.
  • Its Payables stands at $510.3 million for Q4 2025, versus $526.7 million for Q3 2025 and $288.1 million for Q2 2025.